Tags: blood test | rare lung cancer | mesothelioma | asbetos exposure

Blood Test for Lung Cancer

Thursday, 11 Oct 2012 07:50 AM


It may be possible to identify a form of lung cancer through a blood test, according to scientists.

The blood test, along with a lung fluid test, looks for a protein in plasma called fibulin-3 that indicates whether a person has mesothelioma, which is often triggered by asbestos exposure and is typically difficult to diagnose, or was simply exposed to asbestos.

"In the mesothelioma patients, fibulin-3 was four to five times higher than in asbestos-exposed individuals," said study author Dr. Harvey Pass, a professor of thoracic oncology at NYU Langone Medical Center in New York City.

Results of the study appear in the Oct. 11 issue of the New England Journal of Medicine.

Mesothelioma develops in the linings of the lungs, chest, abdomen, and heart. A major risk factor for the disease is working or living in areas where asbestos is present, according to the U.S. National Cancer Institute. That risk is made worse if someone smokes. Asbestos, a fibrous material resistant to heat and many chemicals, was used in many construction and plumbing products. It's also found in brake parts on cars and trucks, according to the U.S. Environmental Protection Agency.

Mesothelioma may develop years, often decades after exposure to asbestos, said Pass. Symptoms of the disease include shortness of breath, cough, chest pain, weight loss, and night sweats. By the time people are diagnosed with mesothelioma, the survival time is often about 12 months, Pass said.

That's why Pass and his team have been trying to identify a so-called "biomarker," such as fibulin-3, that could lead to earlier detection and probably more effective treatment of mesothelioma.

The researchers tested for fibulin-3 in 92 people with mesothelioma, 136 people who were exposed to asbestos but didn't have cancer, 93 patients with fluid in their lungs that wasn't caused by mesothelioma, and 43 healthy people with no asbestos exposure. The study volunteers came from Detroit and New York City.

They also tested lung fluid in 74 people with mesothelioma, 39 with fluid in their lungs but no cancer, and 54 with fluid in their lungs and a cancer other than mesothelioma.

Plasma levels of fibulin-3 were significantly higher when mesothelioma was present, the study found. And when lung fluid was tested, the researchers had similar results. Again, levels of fibulin-3 were significantly elevated in people with mesothelioma.

Overall, the researchers found that measuring fibulin-3 levels results in a 96.7 sensitivity (the number of correctly identified cancers) and a specificity of 95.5 percent (the number of people correctly identified as not having cancer).

In 2005, Pass reported on another biomarker called osteopontin that looked promising for the early identification of mesothelioma. Other labs had difficulty reproducing the initial success Pass' team had with that biomarker, and Pass said it's not nearly as specific as fibulin-3 appears to be at identifying an increased risk of mesothelioma.

Still, the current work needs to be validated, he said, adding he'd like to do a trial of people who were exposed to asbestos but don't have symptoms to see if fibulin-3 can pick up mesothelioma well before symptoms appear.

Dr. Len Horovitz, an internist and pulmonologist at Lenox Hill Hospital in New York City, said the study findings might prove useful, if confirmed.

"It's interesting to find a marker like this," Horovitz said. "Normal people don't have the marker; you have to have had asbestos exposure. This may be one way to identify people at risk of mesothelioma that you need to follow more closely."

More research is needed to confirm whether the test actually works and can have an impact on extending survival of patients, he said.



© HealthDay

   
1Like our page
2Share
Health-News
A new blood test may be able to diagnose mesothelioma, a rare lung cancer that is difficult to spot.
blood test,rare lung cancer,mesothelioma,asbetos exposure
603
2012-50-11
Thursday, 11 Oct 2012 07:50 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved